Dr. Luis David Jimenez Franco joins esqLABS

From July 1, 2021, on Dr. Luis David Jimenez Franco, an engineer and medical physicist with a PhD from the University of Heidelberg is reinforcing esqLABS.



Dr. Luis David Jimenez Franco joins esqLABS

Dr. Luis David Jimenez Franco is is an electronics engineer and medical physicist passionate about applying technical, physical and physiological knowledge to improve people’s quality of life. Before joining esqLABS, he co-developed several physiologically-based pharmacokinetic (PBPK) models for radiopharmaceuticals as well as a PBPK-based algorithm which allows for individualised treatment planning in molecular radiotherapy.

Luis is experienced in clinical and pre-clinical trials for radiopharmaceuticals and has extensive knowledge of medical imaging and internal radiation dosimetry.

Luis studied Electronics Engineering at the Universidad Pontificia Bolivariana (Colombia) and completed Master’s degrees in Engineering (Universidad EAFIT, Colombia) and Medical Physics (University of Heidelberg, Germany). He received his Ph.D. in Medical Physics under the supervision of Prof. Gerhard Glatting.

Peer Reviewed Journal Articles:

  1. Nazari M, Jiménez-Franco LD, Schroeder M, Kluge A, Bronzel M, Kimiaei S. Automated and robust organ segmentation for 3D-based internal dose calculation. EJNMMI Res. 2021 Jun 7;11(1):53
  2. Merkx RIJ, Lobeek D, Konijnenberg M, Jiménez-Franco LD, Kluge A, Oosterwijk E, Mulders PFA, Rijpkema M. Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021 Mar 2.
  3. Kramer V, Fernández R, Lehnert W, Jiménez-Franco LD, Soza-Ried C, Eppard E, Ceballos M, Meckel M, Benešová M, Umbricht CA, Kluge A, Schibli R, Zhernosekov K, Amaral H, Müller C. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients
  4. with mCRPC. Eur J Nucl Med Mol Imaging. 2021 Mar; 48(3): 893-903.
  5. Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, Staudinger F, Tonndorf-Martini E, Regnery S, Rieken S, El Shafie R, Röhrich M, Flechsig P, Kluge A, Altmann A, Debus J, Haberkorn U, Kratochwil C. FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling:
  6. Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med. 2021 Feb; 62(2): 201-207.
  7. Jiménez-Franco LD, Glatting G, Prasad V, Weber WA, Beer AJ, Kletting P. Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment. J Nucl Med. 2021 Jan; 62(1): 92-98.
  8. Fernandez R, Eppard E, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Ceballos M, Ribbeck J, Kluge A, Roesch F, Meckel M, Zhernosekov K, Kramer V, Amaral H. Evaluation of safety and dosimetry of 177Lu DOTA-ZOL for therapy of bone metastases. J Nucl Med. 2021 Jan 8.
  9. Attarwala AA, Hardiansyah D, Romanó C, Jiménez-Franco LD, Roscher M, Wängler B, Glatting G. Performance assessment of the ALBIRA II pre-clinical SPECT S102 system for 99mTc imaging. Ann Nucl Med. 2021 Jan; 35(1): 111-120.
  10. Gruber L, Jiménez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, Schoenberg SO, Reindl W, Orlandi F, Mariani M, Jaschke W, Virgolini I. MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-
  11. Releasing Peptide Receptor Antagonist, in GIST Patients. J Nucl Med. 2020 Dec; 61(12): 1749-1755.
  12. Jiménez-Franco LD, Kletting P, Glatting G. Möglichkeiten zur Verbesserung der Dosimetrie und Therapieplanung in der Molekularen Radiotherapie durch maschinelles Lernen (Possibilities for improving dosimetry and therapy planning in molecular radiotherapy using machine). Der
  13. Nuklearmediziner (Non peer-reviewed). 2019 Jun; 42(02): 148-156.
  14. Winter G, Vogt A, Jiménez-Franco LD, Rinscheid A, Yousefzadeh-Nowshahr E, Solbach C, Beer AJ, Glatting G, Kletting P. Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands. Nucl Med Biol. 2019 May-Jun; 72-73: 20-25.
  15. Jiménez-Franco LD, Kletting P, Beer AJ, Glatting G. Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk. Med Phys. 2018 Jun 15.

Conference Talks:

  1. Gruber L, Decristoforo C, Uprimny C, Kaeopookum P, Jimenez LD, Glatting G, Hohenberger P, Schönberg S, Orlandi F, Mariani M, Jaschke W, Virgolini I. Results of a Phase I/IIa study using 68Ga- NeoBOMB1 in oligometastatic GIST. European Journal of Nuclear Medicine (EANM) Annual Meeting. Barcelona, Spain, 2019.
  2. Kramer V, Fernandez R, Lehnert W, Flores J, Soza-Ried C, Ribbeck J, Ceballos M, Eppard E, Jiménez-Franco LD, Kluge A, Meckel M, Roesch F, Amaral H. Biodistribution and dosimetry of a single dose of [177Lu]Lu-DOTAZOL in patients with mCRPC. European Journal of Nuclear Medicine (EANM) Annual Meeting. Barcelona, Spain, 2019.
  3. Jimenez L, Kletting P, Beer A, Glatting G. Potential benefits of varying the specific activity through the therapy cycles in PRRT with 177Lu- DOTATATE: a simulation study. German Society of Nuclear Medicine (DGN) Annual Meeting. Bremen, Germany, 2019.
  4. Jiménez-Franco LD, Kletting P, Beer A, Glatting G. Prescribing tumour dose in molecular radiotherapy using a PBPK model-based algorithm for individualised treatment planning. European Journal of Nuclear Medicine (EANM) Annual Meeting. Düsseldorf, Germany, 2018.
  5. Jimenez-Franco LD, Leszczynska AK, Glatting G. Allometric scaling of organ volumes and blood flows to generate Bayes parameters for use in PBPK models. German Society of Nuclear Medicine (DGN) Annual Meeting. Poster Presentation. Bremen, Germany, 2018.
  6. Schneider F, Jimenez LD, Bludau F, Jahnke A, Illana C, Fleckenstein J, Clausen S, Obertacke U, Wenz F. Precision IORT – image guided IORT including online CBCT based Monte Carlo treatment planning. Radiotherapy and Oncology. Vienna, Austria, 2017.
  7. Jimenez-Franco LD, Kletting P, Glatting G. Treatment planning in PRRT with 177Lu-DOTATATE considering optimization of the amount, schedule and affinity of a preload substance. Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. Denver, USA, 2017.
  8. Jimenez-Franco LD, Hardiansyah D, Glatting G. Development of a PBPK model of arginine biokinetics in humans to optimize kidney protection during peptide receptor radionuclide therapy. European Journal of Nuclear Medicine (EANM) Annual Meeting. Barcelona, Spain, 2017.
  9. Jimenez LD, Velásquez A, Trefftz H. Evaluation of various strategies to improve the training of a brain-computer interface system. Proceedings of Advances in Computer Science. Phuket, Thailand, 2013.

Get in touch now


ESQlabs GmbH | Am Sportplatz 7 | 26683 Saterland | Germany
Tel. +49 151 / 58559070 | info@esqLABS.com

This site does not use cookies to track your personal information